Vanguard Group Inc Protagonist Therapeutics, Inc Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Vanguard Group Inc holds 4,358,595 shares of PTGX stock, worth $283 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,358,595

Previous 4,277,218 1.9%

Holding current value

$283 Million

Previous $207 Million 16.46%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$40.89 - $56.37 $3.33 Million - $4.59 Million	81,377 Added 1.9%	4,358,595 $241 Million
Q1 2025 May 09, 2025	BUY	$35.09 - $59.76 $2.01 Million - $3.42 Million	57,181 Added 1.35%	4,277,218 $207 Million
Q4 2024 Feb 11, 2025	BUY	$38.51 - $48.43 $152,345 - $191,589	3,956 Added 0.09%	4,220,037 $163 Million
Q3 2024 Nov 13, 2024	BUY	$33.72 - $47.33 $32.8 Million - $46 Million	972,608 Added 29.99%	4,216,081 $189 Million
Q2 2024 Aug 13, 2024	BUY	$24.66 - $34.8 $1.25 Million - $1.76 Million	50,502 Added 1.58%	3,243,473 $112 Million
Q1 2024 May 10, 2024	BUY	$21.79 - $32.15 $851,008 - $1.26 Million	39,055 Added 1.24%	3,192,971 $92.4 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $1.05 Million - $1.75 Million	-74,478 Reduced 2.31%	3,153,916 $72.3 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $1.35 Million - $1.91 Million	80,639 Added 2.56%	3,228,394 $53.8 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $1.69 Million - $2.75 Million	-93,538 Reduced 2.89%	3,147,755 $86.9 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $1.55 Million - $3.64 Million	143,579 Added 4.63%	3,241,293 $74.5 Million
Q4 2022 Feb 10, 2023	BUY	$7.36 - $11.17 $1.14 Million - $1.73 Million	154,947 Added 5.27%	3,097,714 $33.8 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $1.63 Million - $2.44 Million	208,002 Added 7.61%	2,942,767 $24.8 Million
Q2 2022 Aug 12, 2022	BUY	$7.06 - $25.52 $2.86 Million - $10.3 Million	404,691 Added 17.37%	2,734,765 $21.6 Million
Q1 2022 May 13, 2022	SELL	$23.34 - $36.08 $422,267 - $652,759	-18,092 Reduced 0.77%	2,330,074 $55.2 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $99,080 - $208,502	-5,620 Reduced 0.24%	2,348,166 $80.3 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $49.69 $851,488 - $3.27 Million	65,752 Added 2.87%	2,353,786 $41.7 Million
Q2 2021 Aug 13, 2021	BUY	$25.57 - $44.88 $58.5 Million - $103 Million	2,288,034 New	2,288,034 $103 Million

Others Institutions Holding PTGX

# of Institutions

297

Shares Held

67.4M

Call Options Held

290K

Put Options Held

318K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $3.18B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Protagonist Therapeutics, Inc Transaction History